Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P28566

UPID:
5HT1E_HUMAN

ALTERNATIVE NAMES:
S31; Serotonin receptor 1E

ALTERNATIVE UPACC:
P28566; E1P503; Q9P1Y1

BACKGROUND:
5-hydroxytryptamine receptor 1E, also referred to as S31 or Serotonin receptor 1E, plays a crucial role as a G-protein coupled receptor. It engages with serotonin and a variety of alkaloids and psychoactive substances, triggering a signaling cascade through G proteins. This process results in the modulation of adenylate cyclase's activity, leading to its inhibition.

THERAPEUTIC SIGNIFICANCE:
The exploration of 5-hydroxytryptamine receptor 1E's functionality paves the way for innovative therapeutic approaches. Given its significant role in modulating serotonin pathways, targeting this receptor could offer new avenues for treating serotonin-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.